Market Overview

Vivus Downgraded Earlier by Lazard on News of Poorly Performing Treatment

Share:
Related VVUS
Earnings Scheduled For March 9, 2016
Vivus And Oreixigen Have Too Many Problems For Investors, RBC's Simeonidis Claims

Vivus (NASDAQ: VVUS) is currently up nearly 2 percent despite being downgraded from Buy to Neutral at Lazard Capital Markets.

Traders in Vivus are continuing to responding to news from Monday the company's CEO said the company is in discussions with larger pharma companies.

Analyst Joshua Schimmer cited Vivus's obesity treatment drug Qsymia as the culprit, saying demand for the product has failed to meet estimates.

While Vivus is in partnering talks with other pharmaceuticals, it needs to find commercial success for the product or significantly reduce costs in order to slow the current cash outflow, according to Schimmer.

VVUS is trading at 13.76 at last check.

Latest Ratings for VVUS

DateFirmActionFromTo
Feb 2016RBC CapitalDowngradesOutperformSector Perform
Nov 2014Bank of AmericaMaintainsUnderperform
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for VVUS
View the Latest Analyst Ratings

Posted-In: Downgrades Analyst Ratings

 

Related Articles (VVUS)

View Comments and Join the Discussion!